Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Update

Seres Therapeutics, Inc. (NASDAQ:MCRB) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totaling 219,815 shares, a decline of 54.1% from the May 31st total of 478,817 shares. Based on an average trading volume of 102,140 shares, the short-interest ratio is currently 2.2 days. Currently, 2.4% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MCRB. Canaccord Genuity Group reiterated a “buy” rating and set a $22.00 target price on shares of Seres Therapeutics in a research report on Friday, March 13th. Wall Street Zen raised Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings downgraded Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a report on Tuesday, June 23rd. Finally, HC Wainwright started coverage on shares of Seres Therapeutics in a research report on Tuesday, June 23rd. They set a “buy” rating and a $12.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Seres Therapeutics has an average rating of “Hold” and a consensus price target of $17.00.

Hedge Funds Weigh In On Seres Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Seres Therapeutics by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after acquiring an additional 19,793 shares in the last quarter. Invesco Ltd. boosted its position in shares of Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 89,995 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Seres Therapeutics by 4.8% in the fourth quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock valued at $1,536,000 after purchasing an additional 4,723 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Seres Therapeutics in the second quarter valued at $1,016,000. Finally, Geode Capital Management LLC increased its position in Seres Therapeutics by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after purchasing an additional 1,160 shares during the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Price Performance

Shares of MCRB stock opened at $7.08 on Monday. The company’s fifty day simple moving average is $7.36 and its two-hundred day simple moving average is $10.45. Seres Therapeutics has a 52 week low of $5.31 and a 52 week high of $29.98. The stock has a market cap of $68.56 million, a P/E ratio of -1.37 and a beta of 0.12.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.88) by ($0.20). The firm had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.36 million. On average, analysts anticipate that Seres Therapeutics will post -5.84 EPS for the current fiscal year.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.